Clinical Trial Update: SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial comparing an SGLT2 inhibitor to metformin as standard treatment for early-stage Type 2 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• SGLT2 inhibitor
• metformin (metformin)

Snippet

Sponsor: Uppsala University | Conditions: Type 2 Diabetes | Phase 4 | Status: COMPLETED